Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
February 21 2024 - 8:00AM
Business Wire
Novel compounds protected under Enveric’s
intellectual property portfolio provide potential licensing
opportunities and non-dilutive revenue streams.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
a biotechnology company dedicated to the development of novel
neuroplastogenic small-molecule therapeutics for the treatment of
depression, anxiety, and addiction disorders, today announced the
discovery of multiple, promising novel compounds sourced using the
company’s Psybrary™ platform and proprietary computational
chemistry and artificial intelligence (AI) drug-discovery system
(PsyAI™). The novel compounds span seven distinct molecule classes
totaling at least 57 unique product opportunities, all of which are
protected by Enveric’s expansive intellectual property portfolio
and represent potential out-licensing opportunities and
non-dilutive revenue streams for the Company.
Together, the novel and distinct molecule classes broaden and
deepen Enveric’s library of assets targeting difficult-to-address
mental health disorders, adding to its lead candidate EB-003, a
first-in-class neuroplastogen designed to eliminate hallucinations,
and EB-002, formerly EB-373, a next generation synthetic prodrug of
the active metabolite, psilocin.
“Our ability to identify EB-003 and EB-002 as our lead drug
candidates was the result of an extensive process in which our
research team analyzed more than one thousand compounds spanning
numerous classes of molecules, utilizing our proprietary PsyAI and
Psybrary platforms,” said Joseph Tucker, Ph.D., Director and CEO of
Enveric. “As a result, Enveric now possesses what we believe to be
one of the most diverse portfolios of potential drug molecules for
the treatment of key, underserved mental health and neurological
disorders. Our dedicated approach to protecting our discoveries
should enable us to generate significant near- and long-term value
for our shareholders via potential partnering and/or licensing
agreements.”
The novel compounds span seven diverse molecule classes and
subclasses, including:
- Novel Serotonin-Norepinephrine-Dopamine Reuptake Inhibitors
(SNDRI)
- Also known as triple reuptake inhibitors (TRIs), SNDRIs are an
emerging class of medications designed to treat severe depression
and anxiety disorders.
- Enveric SNDRI compounds show strong binding to serotonin
transporter (SERT), norepinephrine transporter (NET) and dopamine
transporter (DAT).
- Enveric SNDRI compounds also demonstrate distinct additional
serotonin receptor binding profiles that bear similarities to those
of the antidepressant Nefazodone and the anxiolytic Buspirone.
- Non-selective Serotonin Reuptake Inhibitor (NSRI)
- Enveric NSRI compounds show strong binding to SERT, as well as
to the 5-HT1A receptor, known to be a therapeutically valuable
target.
- Certain of Enveric’s NSRIs demonstrate additional binding to
various serotonin and dopamine family receptors, with binding
profiles similar to the antidepressant Vortioxetine and the
atypical antipsychotic Aripiprazole.
- Novel MDMA Derivatives (EMD) Series
- Twenty novel MDMA derivatives are separated into three
subgroups: Strong 5-HT2A receptor binding, Weak 5-HT2A binding, and
No 5-HT2A receptor binding. Current literature indicates agonism of
the 5-HT2A receptor is linked to hallucination in humans and also
to the induction of neuroplasticity.
- Each subgroup of Enveric’s novel MDMA derivatives demonstrates
unique and expanded receptor binding activity targeting adrenergic
and/or dopaminergic receptors as well as epinephrine/norepinephrine
family receptors. Some of the resulting receptor binding profiles
are similar to the anxiolytic Buspirone, the antiepileptic
Fenfluramine, the ADHD drug Guanfacine, and the atypical
antipsychotic Aripiprazole.
- Bifunctional Psilocin Prodrugs (BPP)
- BPPs are readily absorbed, detectable in plasma, and converted
to therapeutically relevant levels of plasma psilocin, with
demonstrated lower Head Twitch Response (HTR) relative to
psilocybin in mice; HTR is reported in the literature to be a
predictive indicator for hallucination in humans.
- Each BPP parent prodrug demonstrates its own unique binding
profile to serotonin 5-HT1A receptor, 5-HT1B receptor and SERT,
with similarities to anxiolytics Buspirone,
antidepressant/anxiolytic Flesinoxan, and the antidepressant
Paroxetine.
- Novel Psilocin Prodrug (NPP) Series
- NPPs are designed to be metabolized to release therapeutic
levels of systemic psilocin at varying rates, providing treatment
regimen optionality.
- Included in this series are four compounds that can be
converted upon direct intravenous injection to psilocin:
potentially bypassing the need for first-pass metabolism, making
them amenable to non-oral forms of administration (e.g. intranasal,
sublingual, buccal).
- Melatonin-Receptor Agonist (MRA) Series
- Melatonin, a natural indolamine, is essential for regulating
circadian rhythm in mammals and is often used in to treat a variety
of sleep disorders.
- Enveric MRA compounds demonstrate strong binding to the MT1
Melatonin receptor with some being highly selective for MT1 while
others demonstrate expanded target binding profiles similar to the
antidepressants Agomelatine, Vortioxetine, Imipramine, and
Trazodone.
- Neuroplastogenic Antidepressant (NAD-01)
- Designed to induce neuroplasticity and promote long-term
therapeutic benefit in patients suffering from severe depressive
mood disorders.
- Demonstrates neuroplastogenic activity comparable to known
5-HT2A receptor agonist N,N-Dimethyltryptamine (DMT).
- Demonstrates weak 5-HT2A receptor binding affinity and
activation.
- Produces lower Head Twitch Response relative to psilocin and
DMT, while promoting recovery of sucrose preference (SP) in
stressed mice - an accepted model for evaluation of antidepressant
activity.
For more information about Enveric’s novel preclinical compounds
spanning multiple, distinct classes of molecules, please visit:
https://www.enveric.com/psybrary.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company
dedicated to the development of novel neuroplastogenic
small-molecule therapeutics for the treatment of depression,
anxiety, and addiction disorders. Leveraging its unique discovery
and development platform, Psybrary™, Enveric has created a robust
intellectual property portfolio of New Chemical Entities for
specific mental health indications. Enveric’s lead program, EB-003,
is a first-in-class approach to the treatment of
difficult-to-address mental health disorders designed to promote
neuroplasticity without inducing hallucinations in the patient.
Enveric is also developing EB-002, formerly EB-373, a next
generation synthetic prodrug of the active metabolite, psilocin,
being studied as a treatment of psychiatric disorders. Enveric is
headquartered in Naples, FL with offices in Cambridge, MA and
Calgary, AB Canada. For more information, please visit
www.enveric.com.
Forward-Looking Statements
This press release contains forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. These statements relate to future events or future
performance. All statements other than statements of historical
fact may be forward-looking statements or information. Generally,
forward-looking statements and information may be identified by the
use of forward-looking terminology such as “plans,” “expects” or
“does not expect,” “proposed,” “is expected,” “budgets,”
“scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or
“does not anticipate,” or “believes,” or variations of such words
and phrases, or by the use of words or phrases which state that
certain actions, events or results may, could, should, would, or
might occur or be achieved. Forward-looking statements may include
historical statements and statements regarding beliefs, plans,
expectations, or intentions regarding the future and are based on
the beliefs of management as well as assumptions made by and
information currently available to management. Actual results could
differ materially from those contemplated by the forward-looking
statements as a result of certain factors, including, but not
limited to, the ability of Enveric to: carry out successful
clinical programs in Australia; achieve the value creation
contemplated by technical developments; avoid delays in planned
clinical trials; establish that potential products are efficacious
or safe in preclinical or clinical trials; establish or maintain
collaborations for the development of therapeutic candidates;
obtain appropriate or necessary governmental approvals to market
potential products; obtain future funding for product development
and working capital on commercially reasonable terms; scale-up
manufacture of product candidates; respond to changes in the size
and nature of competitors; hire and retain key executives and
scientists; secure and enforce legal rights related to Enveric’s
products, including patent protection; identify and pursue
alternative routes to capture value from its research and
development pipeline assets; continue as a going concern; and
manage its future growth effectively.
A discussion of these and other factors, including risks and
uncertainties with respect to Enveric, is set forth in Enveric’s
filings with the Securities and Exchange Commission, including
Enveric’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Enveric disclaims any intention or obligation to revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240221498747/en/
Investor Relations Tiberend Strategic Advisors, Inc.
Daniel Kontoh-Boateng (862) 213-1398
dboateng@tiberend.com
Media Relations Tiberend Strategic Advisors, Inc.
Casey McDonald (646) 577-8520 cmcdonald@tiberend.com
Enveric Biosciences (NASDAQ:ENVB)
Historical Stock Chart
From Apr 2024 to May 2024
Enveric Biosciences (NASDAQ:ENVB)
Historical Stock Chart
From May 2023 to May 2024